Kyowa Kirin’s Poteligeo provides progression-free survival in CTCL trial

13th October 2020 (Last Updated October 13th, 2020 16:57)

Kyowa Kirin has reported that the MAVORIC trial of Poteligeo (mogamulizumab) in patients with mycosis fungoides (MF) and Sézary syndrome (SS) achieved overall investigator-assessed progression-free survival (PFS).

Kyowa Kirin’s Poteligeo provides progression-free survival in CTCL trial
The primary endpoint of MAVORIC trial is progression-free survival. Credit: ZaldyImg on Unsplash.

Kyowa Kirin has reported that the MAVORIC trial of Poteligeo (mogamulizumab) in patients with mycosis fungoides (MF) and Sézary syndrome (SS) achieved overall investigator-assessed progression-free survival (PFS).

MF and SS are two types of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin’s lymphoma that affects the skin, blood, lymph nodes and internal organs.

Poteligeo is a monoclonal antibody that attaches to CC chemokine receptor 4 (CCR4) thereby boosting the affinity of immune cells to target cancerous cells.

The randomised trial on patients with MF and SS analysed Poteligeo in providing PFS as a primary endpoint. It also assessed disease progression in the skin, blood, lymph nodes and internal organs.

Secondary endpoints of the trial were overall response rate (ORR), duration of response, the proportion of patients with an overall response in the crossover portion of the trial, assessment of quality of life, immunogenicity and safety.

The data showed superior PFS for patients treated with mogamulizumab as compared to vorinostat, at 7.7 months and 3.1 months, respectively.

On stratification of data by blood classification, PFS was noted to be higher for mogamulizumab compared to vorinostat in patients with higher levels of blood involvement, known as B1 and B2 blood classifications.

Higher levels of blood tumour involvement were linked to better patient outcomes in patients treated with mogamulizumab, results showed.

Mogamulizumab demonstrated higher ORR of 28% as compared to vorinostat at 5%.

Kyowa Kirin Medical Affairs (EMEA) executive vice-president Danie du Plessis said: “Research suggests that patients with B1 and B2 blood classifications may have reductions in median survival and an increased risk of disease progression, compared to those classified as B0.

“Through our work with this therapy, we are aiming to address the unmet needs in these patient populations and are dedicated to improving outcomes for people with MF and SS.”

In February this year, Kyowa Kirin reported positive safety results from the MAVORIC trial of Poteligeo in patients with CTCL.